Short-term prevention of perimenstrual migraine with rimegepant
Abstract
BACKGROUND: Menstrually-related migraine (MRM) affects approximately 31–52% of women with migraine and are characterized by increased frequency, severity, and reduced response to conventional therapy during the perimenstrual window. Traditional short-term prevention with non-steroidal anti-inflammatory drugs (NSAIDs) or triptans often fails due to intolerance or contraindications. Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist with indication for both acute and preventive therapy, may offer a novel short-term prophylactic option for perimenstrual migraine. METHODS: This hypothesis-generating case series includes five women, aged 22–42 years, with episodic migraine and regular menstrual cycles, who received rimegepant 75 mg orally disintegrating tablet every other day, initiated two days prior menstruation and continued until two days post-menstruation. Patients recorded daily headache diaries, and key outcomes included reduction of perimenstrual migraine days, overall migraine frequency, tolerability, and adverse events. Follow-up was conducted after 3–4 cycles. RESULTS: Rimegepant prevented perimenstrual attacks in 17/20 cycles (85%) with no treatment-related adverse events in this small cohort. However, sustained monthly migraine day reduction occurred in only one patient (20%). Three patients (60%) experienced delayed migraine onset 3–7 days post-menstruation, suggesting “temporal displacement” rather than complete prevention. All patients…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.